And recently, we explored a new survival/anti-apoptosis mechanism operating in LNCaP human prostate cancer cells which is promoted by arachidonate 5-Lox and is mediated via protein kinase C-epsilon (PKCε) which was found to be associated with a G protein-coupled oxo-eicosatetraenoid receptor (OXER1) for which 5-oxoETE (the active metabolite of 5-Lox) serves as the major ligand [30]. Here, PRKCE is linked to prostate carcinoma.